Clinical Trials
23 trialsNCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT04000529 2025-09-30
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Novartis
Phase 1 Terminated
NCT06805825 2025-09-23
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
Phase 1 Recruiting
NCT07072143 2025-07-18
PARTNER
Azienda Ospedaliera di Padova
Recruiting
NCT03345485 2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2 Completed
NCT02571036 2023-12-13
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT02452424 2020-03-05
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Daiichi Sankyo
Phase 1/2 Terminated
NCT00428220 2019-06-27
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
Phase NA Completed
NCT01831726 2017-03-20
SIGNATURE
Novartis
Phase 2 Completed
NCT01402089 2016-02-02
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Cantonal Hospital of St. Gallen
Phase 4 Completed
NCT01135849 2015-11-17
B-Receptor Signaling in Cardiomyopathy
Stanford University
Completed
NCT00397384 2015-09-30
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00253383 2014-12-19
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
Dartmouth-Hitchcock Medical Center
Phase NA Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00031681 2013-09-30
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Phase 1 Completed
NCT00087191 2013-01-16
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase NA Terminated
NCT00513851 2011-09-27
Phase 1 Study of OSI-930 in Cancer Patients
Astellas Pharma Inc
Phase 1 Completed
NCT00055705 2011-04-26
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00010023 2011-04-05
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NYU Langone Health
Phase 1 Completed
NCT00049296 2010-06-11
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00041808 2005-06-24
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
FeRx
Phase 1/2 Completed